Aziyo Biologics, Inc.

50 articles with Aziyo Biologics, Inc.

• Aziyo Biologics Appoints Dr. C. Randal Mills as Interim President and CEO

  6/21/2022

  Aziyo Biologics, Inc., a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, announced Aziyo co-founder C. Randal Mills, Ph.D., has been appointed interim president and CEO.

• Aziyo Biologics to Report First Quarter 2022 Financial Results on Monday, May 9, 2022

  4/25/2022

  Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that it plans to release its first quarter 2022 earnings results after market close on Monday, May 9, 2022.

• Aziyo Biologics Announces Upcoming KOL Call Hosted by Cowen

  4/12/2022

  Aziyo Biologics, Inc. announced that the Company’s CanGaroo® Envelope will be highlighted in an upcoming Key Opinion Leader Call hosted by Cowen.

• Aziyo Announces FDA 510(k) Submission for CanGaroo® RM, its Next-Generation Biomaterial Envelope Enhanced with Antibiotics

  4/4/2022

  Aziyo Biologics, Inc., announced the Company has filed a 510 premarket notification to the U.S. Food and Drug Administration for CanGaroo® RM Antibacterial Envelope, its next-generation biomaterial envelope for use with implantable electronic devices.

• Aziyo Biologics to Participate in the Lytham Partners Spring 2022 Investor Conference

  3/31/2022

  Aziyo Biologics, Inc. announced that it will be participating in the Lytham Partners Spring 2022 Investor Conference taking place virtually on April 4-7, 2022.

• Aziyo Biologics Reports Fourth Quarter and Full Year 2021 Financial Results

  3/3/2022

  Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today reported financial results for the fourth quarter and full year ended December 31, 2021.

• Aziyo Biologics to Participate in the Cowen 42nd Annual Health Care Conference

  2/23/2022

  Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced the Company will participate in the upcoming 42nd Annual Cowen Health Care Conference.

• Aziyo Biologics to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 3, 2022

  2/17/2022

  Aziyo Biologics, Inc., a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, announced that it plans to release its fourth quarter and full year 2021 earnings results after market close on Thursday, March 3, 2022.

• Aziyo Biologics to Present at the H.C. Wainwright Bioconnect Virtual Conference

  12/27/2021

  Aziyo Biologics, Inc. today announced that members of management will present at the upcoming H.C. Wainwright Bioconnect Virtual Conference.

• Aziyo Biologics Announces Closing of $14.0 Million Private Placement

  12/8/2021

  Aziyo Biologics, Inc., a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, announced the closing of the previously announced private investment in public equity financing.

• Aziyo Biologics Announces $14.0 Million Private Placement

  12/6/2021

  Aziyo Biologics, Inc. (the “Company”) today announced that it has entered into a definitive agreement to sell securities in a private placement that is expected to result in gross proceeds to the Company of approximately $14.0 million, before deducting offering expenses.

• Aziyo Biologics to Participate in Upcoming Virtual Investor Conferences - Nov 15, 2021

  11/15/2021

  Aziyo Biologics, Inc., a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, announced the company will participate in two upcoming virtual investor conferences.

• Aziyo Biologics Reports Third Quarter 2021 Financial Results

  11/9/2021

  Aziyo Biologics, Inc., a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, reported financial results for the three and nine months ended September 30, 2021.

• Aziyo Biologics Provides Business Update and Preliminary Third Quarter 2021 Revenue Results and Announces Timing for Third Quarter 2021 Financial Results

  10/25/2021

  Aziyo Biologics, Inc. (Nasdaq: AZYO), today announced that it was informed by Medtronic that, after conducting a thorough review of customer and patient needs, Medtronic has made the decision to cease distribution of Cellular Bone Matrix (CBM) products.

• Aziyo Biologics to Participate in the 2021 Cantor Global Healthcare Conference

  9/15/2021

  Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced the Company will participate in the upcoming 2021 Cantor Global Healthcare Conference.

• Aziyo Biologics Appoints Peter G. Edwards as General Counsel

  8/31/2021

  Aziyo Biologics, Inc., a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, announced the appointment of Peter G. Edwards as General Counsel.

• Aziyo Biologics Reports Second Quarter 2021 Financial Results

  8/9/2021

  Aziyo Biologics, Inc., a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, reported financial results for the three and six months ended June 30, 2021.

• Aziyo Biologics to Report Second Quarter 2021 Financial Results on Monday, August 9, 2021

  7/26/2021

  Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that it plans to release its second quarter earnings results after market close on Monday, August 9, 2021.

• 

  Excessive Impurities Cause Recall of Pfizer's Anti-Smoking Drug

  7/20/2021

  Pfizer has voluntarily recalled two lots of Chantix 0.5 mg tablets, two lots of Chantix 1 mg tablets, and eight lots of a Chantix kit consisting of 0.5mg/1 mg tablets.

• Aziyo Biologics Comments on June 2nd Voluntary Recall of One Lot of its FiberCel Fiber Viable Bone Matrix

  6/7/2021

  Aziyo Biologics, Inc. (Nasdaq: AZYO) on June 2, 2021 issued a voluntary recall pertaining to a single donor lot of its FiberCel Fiber Viable Bone Matrix, a bone repair product made from human tissue that is used in various orthopedic and spinal procedures.